Immunicum will continue leveraging its core expertise to explore other complementary technologies and platforms. In addition to SUBCUVAX®, these applications will allow the company to pursue or benefit from leading immuno-oncology trends in the biopharmaceutical industry, such as adoptive CAR-T cell therapy.
SUBCUVAX shares the same technology basis as INTUVAX® but in contrast to INTUVAX®, SUBCUVAX® dendritic cells will be transfected outside of the body to express neoantigens, using the Company’s patented adenovirus-vector technology. Thus, the treatment can be easily administered subcutaneously as an immune enhancer to recruit the patient´s own dendritic cell and precursors to the injection site. Thereby, the recruited immune cells can potentially engulf dying SUBCUVAX cells, including their “cargo” of immunogenic neoantigens.
CD70 – Optimized CAR-T development for durability and longevity
CAR-T cell therapy has emerged as one of the most exiting therapeutic concepts in modern immuno-oncology. T cells from peripheral blood are isolated, genetically engineered and expanded ex vivo (outside of the body) before being re-infused into the patients. Immunicum’s CD70 platform was designed using the Company’s core expertise in dendritic cell biology and can provide CAR-T companies with a superior tool for expansion of CAR-T cells with improved anti-tumor activity as well as a higher resistance to oxidative stress and immunosuppressive factors that they must face in the tumor environment. Immunicum’s platform could become a new standard for the expansion of CAR-T cell therapies ex vivo. The Company will collaborate with selected partners in the CAR-T cell space to commercialize this platform.
Immunicum’s AAV-Vector Platform – A versatile adenoviral gene delivery vector with high therapeutic value
Immunicum’s proprietary AAV5 vector can be used to deliver genes, coding for neoantigens and immune-boosting factors, into dendritic cells. This is the scientific basis behind the SUBCUVAX® approach. However, potential applications under investigation at Immunicum and its academic and commercial partners go beyond this concept, by including e.g. novel oncolytic treatments. Notably, a clinical phase I/II study is ongoing in patients with neuroendocrine tumors which should provide initial data supporting the approach. Although Immunicum does not own the rights to this indication, the Company still owns the rights to all subsequent indications.